From bench to bedside – preclinical and early clinical development of the anticancer agent indazolium trans - [ tetrachlorobis ( 1 H -indazole ) ruthenate ( III )] ( KP1019 or FFC14A )

  • Hartinger C
  • Zorbas-seifried S
  • Jakupec M
 et al. 
  • 1

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Author-supplied keywords

  • 1
  • anticancer drugs
  • biological activity
  • complexes
  • ffc14a
  • iii
  • introduction
  • kp1019
  • mode of action
  • of metal-based anticancer
  • ruthenium
  • state of the art

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Christian G Hartinger

  • Stefanie Zorbas-seifried

  • Michael A Jakupec

  • Bernd Kynast

  • Haralabos Zorbas

  • Bernhard K Keppler

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free